Pneumococcal Δpep27 Immunization Attenuates TLRs and NLRP3 Expression and Relieves Murine Ovalbumin-Induced Allergic Rhinitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Allergic rhinitis (AR), one of the most common inflammatory diseases, is caused by immunoglobulin E (IgE)–mediated reactions against inhaled allergens. AR involves mucosal inflammation driven by type 2 helper T (Th2) cells. Previously, it was shown that the Streptococcus pneumoniae pep27 mutant (Δpep27) could prevent and treat allergic asthma by reducing Th2 responses. However, the underlying mechanism of Δpep27 immunization in AR remains undetermined. Here, we investigated the role of Δpep27 immunization in the development and progression of AR and elucidated potential mechanisms. In an ovalbumin (OVA)-induced AR mice model, Δpep27 alleviated allergic symptoms (frequency of sneezing and rubbing) and reduced TLR2 and TLR4 expression, Th2 cytokines, and eosinophil infiltration in the nasal mucosa. Mechanistically, Δpep27 reduced the activation of the NLRP3 inflammasome in the nasal mucosa by down-regulating the Toll-like receptor signaling pathway. In conclusion, Δpep27 seems to alleviate TLR signaling and NLRP3 inflammasome activation to subsequently prevent AR.
Abstract
Allergic rhinitis (AR), one of the most common inflammatory diseases, is caused by immunoglobulin E (IgE)–mediated reactions against inhaled allergens. AR involves mucosal inflammation driven by type 2 helper T (Th2) cells. Previously, it was shown that the Streptococcus pneumoniae pep27 mutant (Δpep27) could prevent and treat allergic asthma by reducing Th2 responses. However, the underlying mechanism of Δpep27 immunization in AR remains undetermined. Here, we investigated the role of Δpep27 immunization in the development and progression of AR and elucidated potential mechanisms. In an ovalbumin (OVA)-induced AR mice model, Δpep27 alleviated allergic symptoms (frequency of sneezing and rubbing) and reduced TLR2 and TLR4 expression, Th2 cytokines, and eosinophil infiltration in the nasal mucosa. Mechanistically, Δpep27 reduced the activation of the NLRP3 inflammasome in the nasal mucosa by down-regulating the Toll-like receptor signaling pathway. In conclusion, Δpep27 seems to alleviate TLR signaling and NLRP3 inflammasome activation to subsequently prevent AR.
참고문헌 (46)
- Peter Small, "Allergic rhinitis", Allergy, Asthma & Clinical Immunology, 14(S2) (2018), Springer Science and Business Media LLC[DOI]
- Stuck BA, "Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis : a controlled clinical trial", J. Allergy Clin. Immunol, 113, pp.663~668 (2004)
- Bauchau V, "Epidemiological characterization of the intermittent and persistent types of allergic rhinitis", Allergy, 60, pp.350~353 (2005)
- Ha Jihyun, "Ten-Year trends and prevalence of asthma, allergic rhinitis, and atopic dermatitis among the Korean population, 2008–2017", Clinical and Experimental Pediatrics, 63(7), pp.278~283 (2020), 대한소아청소년과학회[DOI]
- van de Veen W, "The use of biologics for immune modulation in allergic disease", J. Clin. Invest, 129, pp.1452~1462 (2019)
- Dykewicz MS, "Rhinitis and sinusitis", J. Allergy Clin. Immunol, 125, pp.103~115 (2010)
- Thorburn AN, "TLR2, TLR4 and MyD88 mediate allergic airway disease(AAD)and Streptococcus pneumoniae-induced suppression of AAD", PLoS One, 11, pp.e0156402~ (2016)
- Ryu JH, "Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways", J. Allergy Clin. Immunol, 131, pp.549~561 (2013)
- Kim BG, "Pneumococcal pep27 mutant immunization suppresses allergic asthma in mice", Biochem. Biophys. Res. Commun, 514, pp.210~216 (2019)
- Lee S, "Induction of the pneumococcal vncRS operon by lactoferrin is essential for pneumonia", Virulence, 9, pp.1562~1575 (2018)
- Kim EH, "Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice", Vaccine, 30, pp.2008~2019 (2012)
- 김새해, "The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants", Clinical and Experimental Vaccine Research, 6(1), pp.15~21 (2017), 대한백신학회[DOI]
- Giudice EL, "Needle-free vaccine delivery", Adv. Drug Deliv. Rev, 58, pp.68~89 (2006)
- Kersten G, "Needle-free vaccine delivery", Expert. Opin. Drug Deliv, 4, pp.459~474 (2007)
- Seon SH, "Intranasal immunization with an attenuated pep27 mutant provides protection from influenza virus and secondary pneumococcal infections", J. Infect. Dis, 217, pp.637~640 (2018)
- Bousquet J, "Allergic rhinitis and its impact on asthma", J. Allergy Clin. Immunol, 108, pp.S147~334 (2001)
- Durham SR, "Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte", macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation : relationship to tissue eosinophilia, 1992, pp.148, 2390~2394
- Fransson M, "Up-regulation of Toll-like receptors 2, 3 and 4 in allergic rhinitis", Respir. Res, 6, pp.100~ (2005)
- Zhong Q, "Upregulation of the expression of Toll-like receptor 9 in basophils in patients with allergic rhinitis : An enhanced expression by allergens", Scand. J. Immunol, 93, pp.e13003~ (2021)
- Kirtland ME, "Toll-like receptor agonists as adjuvants for allergen immunotherapy", Front. Immunol, 11, pp.599083~ (2020)
- Yang Z, "NLRP3 inflammasome activation promotes the development of allergic rhinitis via epithelium pyroptosis", Biochem. Biophys. Res. Commun, 522, pp.61~67 (2020)
- Zhang W, "Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model", Int. Immunopharmacol, 83, pp.106394~ (2020)
- Annunziato F, "The 3 major types of innate and adaptive cell-mediated effector immunity", J Allergy Clin Immunol, 135, pp.626~635 (2015)
- Gour N, "IL-4 and IL-13 signaling in allergic airway disease", Cytokine, 75, pp.68~78 (2015)
- Greenfeder S, "Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease", Respir. Res, 2, pp.71~79 (2001)
- Aryan Z, "A new era of targeting the ancient gatekeepers of the immune system : Toll-like agonists in the treatment of allergic rhinitis and asthma", Int. Arch. Allergy Immunol, 164, pp.46~63 (2014)
- Xu H, "Inhibition of TLR4 inhibits allergic responses in murine allergic rhinitis by regulating the NF-κB pathway", Exp. Ther. Med, 18, pp.761~768 (2019)
- Zhao CC, "TLR9 mediates the activation of NLRP3 inflammasome and oxidative stress in murine allergic airway inflammation", Mol. Immunol, 125, pp.24~31 (2020)
- Velasco G, "Toll-like receptor 4 or 2 agonists decrease allergic inflammation", Am. J. Resp. Cell Mol, 32, pp.218~224 (2005)
- Starkhammar M, "Toll-like receptor ligands LPS and poly(I : C)exacerbate airway hyperresponsiveness in a model of airway allergy in mice, independently of inflammation", PLoS One, 9, pp.e104114~ (2014)
- Gupta GK, "CpG oligodeoxynucleotides as TLR9 agonists therapeutic application in allergy and asthma", BioDrugs, 24, pp.225~235 (2010)
- Aryan Z, "Toll-like receptors as targets for allergen immunotherapy", Curr. Opin. Allergy Clin. Immunol, 15, pp.568~574 (2015)
- Hayashi T, "TLR9-based immunotherapy for allergic disease", Am. J. Med, 119, pp.897~ (2006)
- Horak F, "VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis", Expert Opin. Inv. Drug, 20, pp.981~986 (2011)
- Schroder NW, "Lipoteichoic acid(LTA)of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor(TLR)-2, lipopolysaccharide-binding protein(LBP), and CD14, whereas TLR-4 and MD-2 are not involved", J. Biol. Chem, 278, pp.15587~15594 (2003)
- Yoshimura A, "Cutting edge : recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2", J. Immunol, 163, pp.1~5 (1999)
- Goodridge HS, "Phosphorylcholine mimics the effects of ES-62 on macrophages and dendritic cells", Parasite Immunol, 29, pp.127~137 (2007)
- Malley R, "Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection", Proc. Natl. Acad. Sci. USA, 100, pp.1966~1971 (2003)
- Kim BY, "Comparison of antiallergic effects of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine in a murine model of allergic rhinitis", Laryngoscope, 123, pp.2371~2377 (2013)
- Sutterwala FS, "Mechanism of NLRP3 inflammasome activation", Ann. NY Acad. Sci, 1319, pp.82~95 (2014)
- Swanson KV, "The NLRP3 inflammasome : molecular activation and regulation to therapeutics", Nat. Rev. Immunol, 19, pp.477~489 (2019)
- Bauernfeind FG, "Cutting edge : NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression", J. Immunol, 183, pp.787~791 (2009)
- Boucher D, "Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity", J. Exp. Med, 215, pp.827~840 (2018)
- Paul WE, "How are T(H)2-type immune responses initiated and amplified?", Nat. Rev. Immunol, 10, pp.225~235 (2010)
- Caucheteux SM, "IL-1β enhances inflammatory TH2differentiation", J. Allergy Clin. Immunol, 138, pp.898~901 (2016)
- Chen CY, "The cancer prevention, anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway", Int. J. Mol. Sci, 19, pp.2729~ (2018)
